Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome

Background: Ulcerative colitis (UC) and irritable bowel syndrome (IBS) share various similarities in clinical symptoms, pathogenesis, and treatment. UC concurrent IBS tends toward more severe symptoms and worse prognosis, and promising feasible therapies for the overlapping symptoms remains a challenge. Rhubarb peony decoction (RPD) is a well-known traditional Chinese medicine that has been widely applied in treating UC. RPD may exert extensive therapeutic effects on both IBS and UC. However, the common mechanism of its treatment remains unclear. We aimed to assess the potential pharmacological mechanism of RPD in the treatment of overlapping IBS and UC. Methods: The active components and targets of RPD were retrieved from ETCM, TCMSP, BATMAN-TCM, and TCM databases. The disease targets were screened by searching the DrugBank, OMIM, TTD, and PharmGKB databases. PPI network analysis was performed and visualized via the STRING platform and Cytoscape software. GO and KEGG enrichment analyses of the hub genes of RPD were predicted to elucidate the potential molecular mechanism. Subsequently, molecular docking was carried out to verify the combination of active compounds with core targets. Results: By integrating all targets of RPD and disease, a total of 31 bioactive ingredients were identified including quercetin, kaempferol, aloe-emodin, beta-sitosterol, and (+)-catechin, etc. JUN, TP53, MAPK1, RELA, MYC, and ESR1 were explored as potential therapeutic targets among 126 common drug-disease-related targets. They were enriched in the AGE-RAGE signaling pathway in diabetic complications, as well as the NF-kappa B signaling pathway and MAPK signaling pathway. Additionally, some active ingredients were identified as candidates for binding to the hub targets via molecular docking, further suggesting their anti-inflammatory and antioxidative properties. Conclusion: RPD may exert the overall treatment effect for UC and IBS overlap syndrome via the biological mechanism of “multi-ingredients, multi-targets, and multi-pathways” on inflammation, oxidative stress, immune, oncogenicity, and gut microbiota dysbiosis.

[1]  Shupeng Li,et al.  Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and the inflammatory cascade by modulating the PI3K/Akt and JNK/NF-κB pathways , 2022, Archives of medical science : AMS.

[2]  Runping Liu,et al.  Advances in the study of emodin: an update on pharmacological properties and mechanistic basis , 2021, Chinese Medicine.

[3]  Shimin Zhao,et al.  Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis , 2021, Frontiers in Immunology.

[4]  Kun Wang,et al.  Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking , 2021, Evidence-based complementary and alternative medicine : eCAM.

[5]  Cuihua Jiang,et al.  Aloe vera mitigates dextran sulfate sodium-induced rat ulcerative colitis by potentiating colon mucus barrier. , 2021, Journal of ethnopharmacology.

[6]  M. Camilleri,et al.  Irritable bowel syndrome , 2020, The Lancet.

[7]  A. Ford,et al.  Global burden of irritable bowel syndrome: trends, predictions and risk factors , 2020, Nature Reviews Gastroenterology & Hepatology.

[8]  R. Cojocariu,et al.  Irritable Bowel Syndrome and Neurological Deficiencies: Is There A Relationship? The Possible Relevance of the Oxidative Stress Status , 2020, Medicina.

[9]  F. A. Moura,et al.  Close interplay of nitro-oxidative stress, advanced glycation end products and inflammation in inflammatory bowel diseases. , 2020, Current medicinal chemistry.

[10]  R. Young,et al.  Medical Management of Inflammatory Bowel Disease. , 2019, The Surgical clinics of North America.

[11]  H. Weber,et al.  Irritable bowel syndrome and gut microbiota. , 2019, Current opinion in endocrinology, diabetes, and obesity.

[12]  Yan Song,et al.  Dietary Quercetin Increases Colonic Microbial Diversity and Attenuates Colitis Severity in Citrobacter rodentium-Infected Mice , 2019, Front. Microbiol..

[13]  S. Luo,et al.  Rhubarb Peony Decoction ameliorates ulcerative colitis in mice by regulating gut microbiota to restoring Th17/Treg balance. , 2019, Journal of ethnopharmacology.

[14]  Zhongxiang Zhao,et al.  Evaluation of the influence of mirabilite on the absorption and pharmacokinetics of the ingredients in Dahuang-mudan decoction by a validated UPLC/QTOF-MS/MS method. , 2019, Biomedical chromatography : BMC.

[15]  N. Mokhtar,et al.  Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways , 2019, Journal of Crohn's & colitis.

[16]  K. Papadakis,et al.  Mechanisms of Disease: Inflammatory Bowel Diseases. , 2019, Mayo Clinic proceedings.

[17]  B. Lacy,et al.  Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions , 2019, Therapeutic advances in gastroenterology.

[18]  Nitima Tatiya-aphiradee,et al.  Immune response and inflammatory pathway of ulcerative colitis , 2018, Journal of basic and clinical physiology and pharmacology.

[19]  W. Lu,et al.  β‐Sitosterol improves experimental colitis in mice with a target against pathogenic bacteria , 2018, Journal of cellular biochemistry.

[20]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[21]  Wei Zhang,et al.  ETCM: an encyclopaedia of traditional Chinese medicine , 2018, Nucleic Acids Res..

[22]  N. Jeyashoke,et al.  Identification of β-Sitosterol as in Vitro Anti-Inflammatory Constituent in Moringa oleifera. , 2018, Journal of agricultural and food chemistry.

[23]  H. Fan,et al.  Are personalized tongxie formula based on diagnostic analyses more effective in reducing IBS symptoms?-A randomized controlled trial. , 2018, Complementary therapies in medicine.

[24]  Thomas Gaillard,et al.  Evaluation of AutoDock and AutoDock Vina on the CASF-2013 Benchmark , 2018, J. Chem. Inf. Model..

[25]  J. Bernatonienė,et al.  The Role of Catechins in Cellular Responses to Oxidative Stress , 2018, Molecules.

[26]  Kang Ning,et al.  TCM-Mesh: The database and analytical system for network pharmacology analysis for TCM preparations , 2017, Scientific Reports.

[27]  H. Tomita,et al.  p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer , 2017, International journal of molecular sciences.

[28]  L. Peyrin-Biroulet,et al.  Ulcerative colitis , 2017, The Lancet.

[29]  H. Ashida,et al.  Enzymatically synthesized glycogen inhibits colitis through decreasing oxidative stress , 2017, Free radical biology & medicine.

[30]  Yanli Wang,et al.  PubChem BioAssay: 2017 update , 2016, Nucleic Acids Res..

[31]  R. Spiller,et al.  IBS and IBD — separate entities or on a spectrum? , 2016, Nature Reviews Gastroenterology &Hepatology.

[32]  B. Lacy,et al.  Diarrhea‐predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations , 2016, Journal of the American Association of Nurse Practitioners.

[33]  Yong Wang,et al.  BATMAN-TCM: a Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine , 2016, Scientific Reports.

[34]  Yu Cao,et al.  Oxidative Stress and Carbonyl Lesions in Ulcerative Colitis and Associated Colorectal Cancer , 2015, Oxidative medicine and cellular longevity.

[35]  Kívia Queiroz de Andrade,et al.  Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? , 2015, Redox biology.

[36]  M. Torres-Ramos,et al.  Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. , 2014, CNS & neurological disorders drug targets.

[37]  M. Frydenberg,et al.  Polymorphisms in the Inflammatory Pathway Genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG Are Associated with Susceptibility of Inflammatory Bowel Disease in a Danish Cohort , 2014, PloS one.

[38]  Fei Wang,et al.  Aloe-emodin from rhubarb (Rheum rhabarbarum) inhibits lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages. , 2014, Journal of ethnopharmacology.

[39]  D. Dodda,et al.  Targeting oxidative stress attenuates trinitrobenzene sulphonic acid induced inflammatory bowel disease like symptoms in rats: Role of quercetin , 2014, Indian journal of pharmacology.

[40]  Wei Zhou,et al.  TCMSP: a database of systems pharmacology for drug discovery from herbal medicines , 2014, Journal of Cheminformatics.

[41]  J. Schmid,et al.  The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.

[42]  V. Verhasselt,et al.  Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation , 2013, Gut.

[43]  A. Campbell,et al.  Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub‐clinical inflammation and the impact on clinical assessment of disease activity , 2013, Alimentary pharmacology & therapeutics.

[44]  J. Návarová,et al.  Efficacy of quercetin derivatives in prevention of ulcerative colitis in rats , 2013, Interdisciplinary toxicology.

[45]  T. Bernklev,et al.  Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission , 2013, Gastroenterology research and practice.

[46]  A. Ciobica,et al.  Different Profile of Peripheral Antioxidant Enzymes and Lipid Peroxidation in Active and Non-active Inflammatory Bowel Disease Patients , 2013, Digestive Diseases and Sciences.

[47]  D. Ardid,et al.  Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome , 2012, Alimentary pharmacology & therapeutics.

[48]  A. Ford,et al.  Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2012, The American Journal of Gastroenterology.

[49]  L. Peyrin-Biroulet,et al.  Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  N. Talley,et al.  The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study , 2012, Gut.

[51]  Kazuhide Yamamoto,et al.  DNA methylation of colon mucosa in ulcerative colitis patients: Correlation with inflammatory status , 2011, Inflammatory bowel diseases.

[52]  Calvin Yu-Chian Chen,et al.  TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.

[53]  Garrett M Morris,et al.  Using AutoDock for Ligand‐Receptor Docking , 2008, Current protocols in bioinformatics.

[54]  J. Tavernier,et al.  TLR-4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme , 2008, Cellular and Molecular Life Sciences.

[55]  F. Schmidt.  Meta-Analysis , 2008 .

[56]  P. Scully,et al.  Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? , 2006, Gastroenterology.

[57]  G Sullivan,et al.  Variations on a Common Theme? , 2001, Journal of homosexuality.

[58]  K. Abrams,et al.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis , 2001, Gut.

[59]  E. Stein,et al.  Irritable Bowel Syndrome: What Treatments Really Work. , 2019, The Medical clinics of North America.

[60]  Heng Zhang 张 姮,et al.  Expression and clinical significance of IL-17 and IL-17 receptor in ulcerative colitis , 2016, Journal of Huazhong University of Science and Technology [Medical Sciences].